project id: TCGA-ESCA; case submitter id: TCGA-VR-AA4D; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.84; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.54; rna integrity number: 7.3; age at index: 53; days to birth: -19714; days to death: 1405; ethnicity: not reported; gender: male; race: white; vital status: Dead; year of birth: 1957; age at diagnosis: 19714; ajcc clinical m: M0; ajcc clinical n: NX; ajcc clinical stage: Stage IA; ajcc clinical t: T1; ajcc pathologic m: M0; ajcc pathologic n: N1; ajcc pathologic stage: Stage IIB; ajcc pathologic t: T1; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1378.0; icd 10 code: C15.5; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Lower third of esophagus; synchronous malignancy: No; tissue or organ of origin: Lower third of esophagus; tumor grade: Not Reported; year of diagnosis: 2010; treatment or therapy: yes; alcohol history: No; is ffpe: false; composition: Not Reported; days to collection: 1322; days to sample procurement: 0; initial weight: 100.0; portion submitter id: TCGA-VR-AA4D-01A-11; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 1.0; percent necrosis: 10.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 35.0; percent tumor cells: 55.0; percent tumor nuclei: 70.0;